January 3, 2019 07:14 AM EST

Gene silencing company NeuBase Therapeutics to reverse merge its way onto Nasdaq via troubled microcap Ohr

Natalie Grover

Reporter

Dietrich Stephan, one of the pioneers in the field of precision medicine, was in process of raising venture funds for his gene-silencing company NeuBase Therapeutics …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Gene silencing company NeuBase Therapeutics to reverse merge its way onto Nasdaq via troubled microcap Ohr

Natalie Grover

Reporter

Sign up to read this article for free.

Why the Supreme Court's overrule of Chevron has major implications for the FDA

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Scientists unveil new way to make large changes to genes, and no CRISPR is required

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

Biogen is pursuing more dealmaking this year, with plans to spend up to $8B

With a $372M megaround, Formation Bio looks to in-license 10+ drugs

Gene si­lenc­ing com­pa­ny NeuBase Ther­a­peu­tics to re­verse merge its way on­to Nas­daq via trou­bled mi­cro­cap Ohr

Natalie Grover

Reporter

Sign up to read this article for free.

more like this

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

Sci­en­tists un­veil new way to make large changes to genes, and no CRISPR is re­quired

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

Bio­gen is pur­su­ing more deal­mak­ing this year, with plans to spend up to $8B

With a $372M megaround, For­ma­tion Bio looks to in-li­cense 10+ drugs

Gene silencing company NeuBase Therapeutics to reverse merge its way onto Nasdaq via troubled microcap Ohr

Why the Supreme Court's overrule of Chevron has major implications for the FDA

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Scientists unveil new way to make large changes to genes, and no CRISPR is required

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

Biogen is pursuing more dealmaking this year, with plans to spend up to $8B

With a $372M megaround, Formation Bio looks to in-license 10+ drugs